Samuel H. Cheshier
No Rating Available
(Learn About Our Rating System)

Samuel H. Cheshier, MD, PhD

Languages spoken: English

Clinical Locations

Primary Location

Primary Children's Hospital

Pediatric Neurosurgery
100 N Mario Capecchi Drive
Salt Lake City , UT 84113
801-662-5340
Get Directions

As a pediatric neurosurgeon, I witness first-hand the devastation that malignant brain tumors cause both the patients and families. The desire to help these people motivates me to conduct basic science research, with the goal of translating experiments into therapies. My laboratory has been utilizing a powerful immune-therapy strategy where CD47-SIRPa interactions between tumor cells and macrophages are blocked by Hu5F9-G4 in combination with potent immunotherapies including anti-cancer targeted monoclonal antibodies (anti-PDL1, anti-CD44, anti-Her2/Neu, anti-GD2), and modulators of macrophage activity (anti-CD40).

My clinical practice specializing in brain tumor surgery has provided my laboratory with a large number of patient-derived malignant brain tumors from both pediatric and adult patients, which have already been used to conduct an excellent preclinical evaluation of Hu5F9-G4 against five pediatric malignant primary CNS tumors. While I was faculty at Stanford, I was in charge of the preclinical development of Hu5F9-G4 against malignant brain tumors, and I was a participant in the anti-CD47 Disease Team that helped develop the therapy into Phase 1 clinical trial.

Since accepting my position at the Huntsman Cancer Institute, University of Utah School of Medicine as Director of Pediatric Surgical Neuro-Oncology, one of my laboratory’s main goals is to enhance anti-CD47 mediated phagocytosis by promoting the expression of pro-phagocytosis signals on brain cancer cells by irradiation. Irradiation is a well-known enhancer of pro-phagocytosis signal presentation on tumor cells. For example, calreticulin and phosphatidylserine are key pro-phagocytosis signals and are elevated in response to irradiation.

I have developed preliminary data demonstrating anti-CD47 in combination with irradiation increased macrophage phagocytosis of human glioblastoma in vitro and increased survival in human glioblastoma-mouse orthotopic PDX models. Given the known efficacy of irradiation against malignant brain tumors, and the large medical infrastructure already present to deliver irradiation to patients, I feel my proposed studies to combine irradiation with anti-CD47 will provide significant data to justify clinical trials utilizing this combination.

My current and previous research history have provided me a deep understanding (mechanism, efficacy, toxicity, combinatorial strategies) of anti-CD47 therapy in general. My laboratory can conduct the entire range of preclinical experiments testing anti-CD47 in vitro, as well as in mouse models (human-mouse PDX, mouse models of primary brain tumors) to obtain data to justify and help design human trials in brain tumor patients. I believe anti-CD47 will be a foundational immune therapy that will be used as a key reagent in combination with other immune therapies and standard of care treatments.

Specialties

Board Certification

American Board of Pediatric Neurological Surgery
American Board of Neurological Surgery (Neurosurg)

As a pediatric neurosurgeon, I witness first-hand the devastation that malignant brain tumors cause both the patients and families. The desire to help these people motivates me to conduct basic science research, with the goal of translating experiments into therapies. My laboratory has been utilizing a powerful immune-therapy strategy where CD47-SIRPa interactions between tumor cells and macrophages are blocked by Hu5F9-G4 in combination with potent immunotherapies including anti-cancer targeted monoclonal antibodies (anti-PDL1, anti-CD44, anti-Her2/Neu, anti-GD2), and modulators of macrophage activity (anti-CD40).

My clinical practice specializing in brain tumor surgery has provided my laboratory with a large number of patient-derived malignant brain tumors from both pediatric and adult patients, which have already been used to conduct an excellent preclinical evaluation of Hu5F9-G4 against five pediatric malignant primary CNS tumors. While I was faculty at Stanford, I was in charge of the preclinical development of Hu5F9-G4 against malignant brain tumors, and I was a participant in the anti-CD47 Disease Team that helped develop the therapy into Phase 1 clinical trial.

Since accepting my position at the Huntsman Cancer Institute, University of Utah School of Medicine as Director of Pediatric Surgical Neuro-Oncology, one of my laboratory’s main goals is to enhance anti-CD47 mediated phagocytosis by promoting the expression of pro-phagocytosis signals on brain cancer cells by irradiation. Irradiation is a well-known enhancer of pro-phagocytosis signal presentation on tumor cells. For example, calreticulin and phosphatidylserine are key pro-phagocytosis signals and are elevated in response to irradiation.

I have developed preliminary data demonstrating anti-CD47 in combination with irradiation increased macrophage phagocytosis of human glioblastoma in vitro and increased survival in human glioblastoma-mouse orthotopic PDX models. Given the known efficacy of irradiation against malignant brain tumors, and the large medical infrastructure already present to deliver irradiation to patients, I feel my proposed studies to combine irradiation with anti-CD47 will provide significant data to justify clinical trials utilizing this combination.

My current and previous research history have provided me a deep understanding (mechanism, efficacy, toxicity, combinatorial strategies) of anti-CD47 therapy in general. My laboratory can conduct the entire range of preclinical experiments testing anti-CD47 in vitro, as well as in mouse models (human-mouse PDX, mouse models of primary brain tumors) to obtain data to justify and help design human trials in brain tumor patients. I believe anti-CD47 will be a foundational immune therapy that will be used as a key reagent in combination with other immune therapies and standard of care treatments.

Board Certification and Academic Information

Academic Departments Neurosurgery -Associate Professor
Academic Divisions Pediatric Neurosurgery
Board Certification
American Board of Pediatric Neurological Surgery
American Board of Neurological Surgery (Neurosurg)

Education history

Undergraduate Loma Linda University Associates
Undergraduate Psychobiology - University of California, Los Angeles B.S.
Professional Medical Medicine - Stanford University School of Medicine M.D.
Doctoral Training Immunology - Stanford University School of Medicine Ph.D.
Internship Surgery - Stanford University Hospitals and Clinics Intern
Residency Neurosurgery - Stanford University School of Medicine Resident
Postdoctoral Fellowship Neurosurgery and Pathology - Stanford University School of Medicine Postdoctoral Fellow
Research Fellow Stem Cell Biology and Cell Therapy - Lund University Research Fellow
Fellowship Paediatric Neurosurgery - The Hospital for Sick Children Fellow

Selected Publications

Journal Article

  1. Mondal G, Lee JC, Ravindranathan A, Villanueva-Meyer JE, Tran QT, Allen SJ, Barreto J, Gupta R, Doo P, Van Ziffle J, Onodera C, Devine P, Grenert JP, Samuel D, Li R, Metrock LK, Jin LW, Antony R, Alashari M, Cheshier S, Whipple NS, Bruggers C, Raffel C, Gupta N, Kline CN, Reddy A, Banerjee A, Hall MD, Mehta MP, Khatib Z, Maher OM, Brathwaite C, Pekmezci M, Phillips JJ, Bollen AW, Tihan T, Lucas JT Jr, Broniscer A, Berger MS, Perry A, Orr BA, Solomon DA (2020). Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. Acta Neuropathol, 139(6), 1071-1088.
  2. Cole AP, Hoffmeyer E, Chetty SL, Cruz-Cruz J, Hamrick F, Youssef O, Cheshier S, Mitra SS (2020). Microglia in the Brain Tumor Microenvironment. Adv Exp Med Biol, 1273, 197-208.
  3. Quon JL, Bala W, Chen LC, Wright J, Kim LH, Han M, Shpanskaya K, Lee EH, Tong E, Iv M, Seekins J, Lungren MP, Braun KRM, Poussaint TY, Laughlin S, Taylor MD, Lober RM, Vogel H, Fisher PG, Grant GA, Ramaswamy V, Vitanza NA, Ho CY, Edwards MSB, Cheshier SH, Yeom K (2020). Deep Learning for Pediatric Posterior Fossa Tumor Detection and Classification: A Multi-Institutional Study. AJNR. American journal of neuroradiology, 41(9), 1718-1725.
  4. Zhang M, Wong SW, Lummus S, Han M, Radmanesh A, Ahmadian SS, Prolo LM, Lai H, Eghbal A, Oztekin O, Cheshier SH, Fisher PG, Ho CY, Vogel H, Vitanza NA, Lober RM, Grant GA, Jaju A, Yeom K (2021). Radiomic Phenotypes Distinguish Atypical Teratoid/Rhabdoid Tumors from Medulloblastoma. AJNR. American journal of neuroradiology, 42(9), 1702-1708.
  5. Mohole J, Ho AL, Cannon JGD, Pendharkar AV, Sussman ES, Hong DS, Cheshier SH, Grant G (2019). Topical Vancomycin for Surgical Prophylaxis in Pediatric Craniofacial Surgeries. The Journal of craniofacial surgery, 30(7), 2163-2167.
  6. Lucas CG, Villanueva-Meyer JE, Whipple N, Oberheim Bush NA, Cooney T, Chang S, McDermott M, Berger M, Cham E, Sun PP, Putnam A, Zhou H, Bollo R, Cheshier S, Poppe MM, Fung KM, Sung S, Glenn C, Fan X, Bannykh S, Hu J, Danielpour M, Li R, Alva E, Johnston J, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Pekmezci M, Tihan T, Bollen AW, Perry A, Solomon D (2020). Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features. Brain pathology (Zurich, Switzerland), 30(3), 479-494.
  7. Hamrick FA, Karsy M, Bruggers CS, Putnam AR, Hedlund GL, Cheshier S (2021). Developmentally anomalous cerebellar encephalocele arising within the cerebellopontine angle and extending into the adjacent skull base in a pediatric patient. Child's nervous system, 37(9), 2943-2947.
  8. Zhang M, Wong SW, Wright JN, Toescu S, Mohammadzadeh M, Han M, Lummus S, Wagner MW, Yecies D, Lai H, Eghbal A, Radmanesh A, Nemelka J, Harward S, Malinzak M, Laughlin S, Perreault S, Braun KRM, Vossough A, Poussaint T, Goetti R, Ertl-Wagner B, Ho CY, Oztekin O, Ramaswamy V, Mankad K, Vitanza NA, Cheshier SH, Said M, Aquilina K, Thompson E, Jaju A, Grant GA, Lober RM, Yeom K (2021). Machine Assist for Pediatric Posterior Fossa Tumor Diagnosis: A Multinational Study. Neurosurgery, 89(5), 892-900.
  9. Iv M, Ng NN, Nair S, Zhang Y, Lavezo J, Cheshier SH, Holdsworth SJ, Moseley ME, Rosenberg J, Grant GA, Yeom K (2020). Brain Iron Assessment after Ferumoxytol-enhanced MRI in Children and Young Adults with Arteriovenous Malformations: A Case-Control Study. Radiology, 297(2), 438-446.
  10. Morales E, Viskochil D, Hofmann J, Hagedorn C, Linscott L, Cheshier S, Bruggers C (2021). Multiple Intraspinal Gangliogliomas in a Child With Neurofibromatosis Type 1: Case Report and Literature Review. Journal of pediatric hematology/oncology, 43(7), e979-e982.
  11. Theruvath J, Sotillo E, Mount CW, Graef CM, Delaidelli A, Heitzeneder S, Labanieh L, Dhingra S, Leruste A, Majzner RG, Xu P, Mueller S, Yecies DW, Finetti MA, Williamson D, Johann PD, Kool M, Pfister S, Hasselblatt M, Frühwald MC, Delattre O, Surdez D, Bourdeaut F, Puget S, Zaidi S, Mitra SS, Cheshier S, Sorensen PH, Monje M, Mackall C (2020). Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nature medicine, 26(5), 712-719.
  12. Higgins DMO, Caliva M, Schroeder M, Carlson B, Upadhyayula PS, Milligan BD, Cheshier SH, Weissman IL, Sarkaria JN, Meyer FB, Henley J (2020). Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas. BMC cancer, 20(1), 1213.
  13. Shpanskaya K, Quon JL, Lober RM, Nair S, Johnson E, Cheshier SH, Edwards MSB, Grant GA, Yeom K (2019). Diffusion tensor magnetic resonance imaging of the optic nerves in pediatric hydrocephalus. Neurosurgical focus, 47(6), E16.
  14. Cheshier S, Taylor MD, Ayrault O, Mueller (2020). Introduction. Pediatric brain tumor. Neurosurgical focus, 48(1), E1.
  15. Huang Y, Singer TG, Iv M, Lanzman B, Nair S, Stadler JA, Wang J, Edwards MSB, Grant GA, Cheshier SH, Yeom K (2019). Ferumoxytol-enhanced MRI for surveillance of pediatric cerebral arteriovenous malformations. Journal of neurosurgery. Pediatrics, 1-8.
  16. Quon JL, Kim LH, Hwang PH, Patel ZM, Grant GA, Cheshier SH, Edwards MS (2019). Transnasal endoscopic approach for pediatric skull base lesions: a case series. Journal of neurosurgery. Pediatrics, 1-12.
  17. Yecies D, Shpanskaya K, Jabarkheel R, Maleki M, Bruckert L, Cheshier SH, Hong D, Edwards MSB, Grant GA, Yeom K (2019). Arterial spin labeling perfusion changes of the frontal lobes in children with posterior fossa syndrome. Journal of neurosurgery. Pediatrics, 1-7.
  18. Quon JL, Han M, Kim LH, Koran ME, Chen LC, Lee EH, Wright J, Ramaswamy V, Lober RM, Taylor MD, Grant GA, Cheshier SH, Kestle JRW, Edwards MSB, Yeom K (2020). Artificial intelligence for automatic cerebral ventricle segmentation and volume calculation: a clinical tool for the evaluation of pediatric hydrocephalus. Journal of neurosurgery. Pediatrics, 27, 1-8.
  19. Gholamin S, Youssef OA, Rafat M, Esparza R, Kahn S, Shahin M, Giaccia AJ, Graves EE, Weissman I, Mitra S, Cheshier S (2020). Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma. Innate immunity, 26(2), 130-137.
  20. SoRelle ED, Yecies DW, Liba O, Bennett FC, Graef CM, Dutta R, Mitra S, Joubert LM, Cheshier S, Grant GA, de la Zerda (2019). Spatiotemporal Tracking of Brain-Tumor-Associated Myeloid Cells in Vivo through Optical Coherence Tomography with Plasmonic Labeling and Speckle Modulation. ACS nano, 13(7), 7985-7995.
  21. Gardner M, Turner JE, Youssef OA, Cheshier (2020). In Vitro Macrophage-Mediated Phagocytosis Assay of Brain Tumors. Cureus, 12(10), e10964.
  22. Quon JL, Chen LC, Kim L, Grant GA, Edwards MSB, Cheshier SH, Yeom K (2020). Deep Learning for Automated Delineation of Pediatric Cerebral Arteries on Pre-operative Brain Magnetic Resonance Imaging. Frontiers in surgery, 7, 517375.
  23. Tam LT, Yeom KW, Wright JN, Jaju A, Radmanesh A, Han M, Toescu S, Maleki M, Chen E, Campion A, Lai HA, Eghbal AA, Oztekin O, Mankad K, Hargrave D, Jacques TS, Goetti R, Lober RM, Cheshier SH, Napel S, Said M, Aquilina K, Ho CY, Monje M, Vitanza NA, Mattonen S (2021). MRI-based radiomics for prognosis of pediatric diffuse intrinsic pontine glioma: an international study. Neuro-oncology advances, 3(1), vdab042.
  24. Lucas CG, Abdullaev Z, Bruggers CS, Mirchia K, Whipple NS, Alashari MM, Lowichik A, Cheshier S, Phillips JJ, Devine P, Solomon DA, Quezado M, Aldape KD, Perry (2022). Activating NTRK2 and ALK receptor tyrosine kinase fusions extend the molecular spectrum of pleomorphic xanthoastrocytomas of early childhood: a diagnostic overlap with infant-type hemispheric glioma. Acta neuropathologica, 143(2), 283-286.
  25. Ojha R, Tantray I, Rimal S, Mitra S, Cheshier S, Lu (2022). Regulation of reverse electron transfer at mitochondrial complex I by unconventional Notch action in cancer stem cells. Developmental cell, 57(2), 260-276.e9.
  26. Zhang M, Wang E, Yecies D, Tam LT, Han M, Toescu S, Wright JN, Altinmakas E, Chen E, Radmanesh A, Nemelka J, Oztekin O, Wagner MW, Lober RM, Ertl-Wagner B, Ho CY, Mankad K, Vitanza NA, Cheshier SH, Jacques TS, Fisher PG, Aquilina K, Said M, Jaju A, Pfister S, Taylor MD, Grant GA, Mattonen S, Ramaswamy V, Yeom K (2021). Radiomic Signatures of Posterior Fossa Ependymoma: Molecular Subgroups and Risk Profiles. Neuro-oncology, 24, 986-994.
  27. Thomsen W, Maese L, Vagher J, Moore K, Cheshier SH, Hofmann JW, Bruggers (2021). Early Presentation of Homozygous Mismatch Repair Deficient Glioblastoma in Teen With Lynch Syndrome: Implications for Treatment and Surveillance. JCO precision oncology, 5, 670-675.
  28. Zhang M, Tam L, Wright J, Mohammadzadeh M, Han M, Chen E, Wagner M, Nemalka J, Lai H, Eghbal A, Ho CY, Lober RM, Cheshier SH, Vitanza NA, Grant GA, Prolo LM, Yeom KW, Jaju (2022). Radiomics Can Distinguish Pediatric Supratentorial Embryonal Tumors, High-Grade Gliomas, and Ependymomas. AJNR. American journal of neuroradiology, 43, 603-610.
  29. Zhang M, Wong SW, Wright JN, Wagner MW, Toescu S, Han M, Tam LT, Zhou Q, Ahmadian SS, Shpanskaya K, Lummus S, Lai H, Eghbal A, Radmanesh A, Nemelka J, Harward S 2nd, Malinzak M, Laughlin S, Perreault S, Braun KRM, Lober RM, Cho YJ, Ertl-Wagner B, Ho CY, Mankad K, Vogel H, Cheshier SH, Jacques TS, Aquilina K, Fisher PG, Taylor M, Poussaint T, Vitanza NA, Grant GA, Pfister S, Thompson E, Jaju A, Ramaswamy V, Yeom K (2022). MRI Radiogenomics of Pediatric Medulloblastoma: A Multicenter Study. Radiology, 304, 212137.
  30. Lucas CG, Davidson CJ, Alashari M, Putnam AR, Whipple NS, Bruggers CS, Mendez JS, Cheshier SH, Walker JB, Ramani B, Cadwell CR, Sullivan DV, Lu R, Mirchia K, Van Ziffle J, Devine P, Goldschmidt E, Hervey-Jumper SL, Gupta N, Oberheim Bush NA, Raleigh DR, Bollen A, Tihan T, Pekmezci M, Solomon DA, Phillips JJ, Perry (2022). Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma. Journal of neuropathology and experimental neurology, 81(8), 650-657.
  31. Wu Z, Rajan S, Chung HJ, Raffeld M, Panneer Selvam P, Schweizer L, Perry A, Samuel D, Giannini C, Ragunathan A, Frosch MP, Marshall MS, Boué DR, Donev K, Neill SG, Fernandes I, Resnick A, Rood B, Cummings TJ, Buckley AF, Szymanski L, Neto OLA, Zach L, Colman H, Cheshier S, Ziskin J, Tyagi M, Capper D, Abdullaev Z, Cimino PJ, Quezado M, Pratt D, Aldape (2022). Molecular and clinicopathologic characteristics of gliomas with EP300::BCOR fusions. Acta neuropathologica, 144(6), 1175-1178.
  32. Baker C, Crevelt J, Whipple N, Bollo RJ, Cheshier (2022). Treatment of a symptomatic thalamic pilocytic astrocytoma with reservoir placement and laser interstitial thermal therapy: illustrative case. Journal of neurosurgery. Case lessons, 3(11),
  33. Brockmeyer DL, Cheshier SH, Stevens J, Facelli JC, Rowe K, Heiss JD, Musolf A, Viskochil DH, Allen-Brady KL, Cannon-Albright L (2022). A likely HOXC4 predisposition variant for Chiari malformations. Journal of neurosurgery, 139(1), 266-274.
  34. Marquardt V, Theruvath J, Pauck D, Picard D, Qin N, Blümel L, Maue M, Bartl J, Ahmadov U, Langini M, Meyer FD, Cole A, Cruz-Cruz J, Graef CM, Wölfl M, Milde T, Witt O, Erdreich-Epstein A, Leprivier G, Kahlert U, Stefanski A, Stühler K, Keir ST, Bigner DD, Hauer J, Beez T, Knobbe-Thomsen CB, Fischer U, Felsberg J, Hansen FK, Vibhakar R, Venkatraman S, Cheshier SH, Reifenberger G, Borkhardt A, Kurz T, Remke M, Mitra (2023). Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. Journal for immunotherapy of cancer, 11(1), e005871.
  35. Ravindra VM, Robinson L, Jensen H, Kurudza E, Joyce E, Ludwick A, Telford R, Youssef O, Ryan J, Bollo RJ, Iyer RR, Kestle JRW, Cheshier SH, Ikeda DS, Mao Q, Brockmeyer D (2024). Morphological and ultrastructural investigation of the posterior atlanto-occipital membrane: Comparing children with Chiari malformation type I and controls. PloS one, 19(1), e0296260.
  36. Lee EH, Han M, Wright J, Kuwabara M, Mevorach J, Fu G, Choudhury O, Ratan U, Zhang M, Wagner MW, Goetti R, Toescu S, Perreault S, Dogan H, Altinmakas E, Mohammadzadeh M, Szymanski KA, Campen CJ, Lai H, Eghbal A, Radmanesh A, Mankad K, Aquilina K, Said M, Vossough A, Oztekin O, Ertl-Wagner B, Poussaint T, Thompson EM, Ho CY, Jaju A, Curran J, Ramaswamy V, Cheshier SH, Grant GA, Wong SS, Moseley ME, Lober RM, Wilms M, Forkert ND, Vitanza NA, Miller JH, Prolo LM, Yeom K (2024). An international study presenting a federated learning AI platform for pediatric brain tumors. Nature communications, 15(1), 7615.
  37. Greiner D, Xue Q, Waddell TQ, Kurudza E, Chaudhary P, Belote RL, Dotti G, Judson-Torres RL, Reeves MQ, Cheshier SH, Roh-Johnson (2025). Human CSPG4-targeting CAR-macrophages inhibit melanoma growth. Oncogene, 44(22), 1665-1677.
  38. Pathuri S, Nguyen S, Yengo-Kahn AM, Cheshier SH, Bollo R (2025). Laser ablation of a fourth ventricular hamartoma causing medically refractory hemifacial spasms in a child: illustrative case. Journal of neurosurgery. Case lessons, 9(10),
  39. Almer AG, Rasmussen SV, Kats D, Svalina MN, Cole BL, Khani M, Chen S, Cheshier SH, Martin BA, Berlow NE, Keller (2025). Computational and biological modeling of IGF1R inhibition for multifocal medulloblastoma. Communications medicine, 5(1), 206.

Review

  1. Giberson CE, Cheshier SH, Poree LR, Saulino M (2023). Diaphragm Pacing: A Safety, Appropriateness, Financial Neutrality, and Efficacy Analysis of Treating Chronic Respiratory Insufficiency. Neuromodulation, 26(3), 490-497.
  2. Boeckermann L, Menjivar D, Hagn EE, Previtera M, Cheshier SH, McCrary HC, Alt J (2025). Evaluating Methodology for Increasing Diversity in US Residency Training Programs: A Scoping Review. Journal of graduate medical education, 17(5), 579-594.

Book Chapter

  1. Cheshier SH, Doz F, Ellison D, Merchant TE and Pfister S (2023). Embryonal tumours.

Case Report

  1. Pan J, Ho AL, Pendharkar AV, Sussman ES, Casazza M, Cheshier SH, Grant G (2019). Brain abscess caused by Trueperella bernardiae in a child. Surgical neurology international, 10, 35.

Editorial

  1. Bruggers CS, Linscott L, Lee JC, Perry A, Klonoski J, Viskochil D, Cheshier S, Afify (2022). Molecular characterization of metachronous atypical teratoid rhabdoid tumors occurring in a young man 15 years apart. Pediatric blood & cancer, 70(1), e29836.

Other

  1. Hamrick FA, Karsy M, Bruggers CS, Putnam AR, Hedlund GL, Cheshier S (2021). Correction to: Developmentally anomalous cerebellar encephalocele arising within the cerebellopontine angle and extending into the adjacent skull base in a pediatric patient. Child's nervous system, 37(12), 3977.

Research Lab

Lab link

News & Podcasts

Huntsman Cancer Institute News